Celldex Therapeutics, Inc.
CLDX
$18.30
$0.502.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -71.56% | 110.35% | 832.09% | -83.87% | 156.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -71.56% | 110.35% | 832.09% | -83.87% | 156.11% |
| Cost of Revenue | 54.27% | 31.06% | 56.05% | 18.15% | 32.87% |
| Gross Profit | -74.04% | -27.42% | 37.60% | -21.97% | -23.53% |
| SG&A Expenses | 16.20% | 22.30% | 26.41% | 37.09% | 33.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.71% | 29.38% | 45.83% | 21.91% | 33.09% |
| Operating Income | -59.50% | -26.40% | -39.49% | -25.06% | -25.97% |
| Income Before Tax | -8.74% | -10.09% | -17.51% | -11.74% | -63.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.74% | -10.09% | -17.51% | -11.74% | -63.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.74% | -10.09% | -17.51% | -11.74% | -63.50% |
| EBIT | -59.50% | -26.40% | -39.49% | -25.06% | -25.97% |
| EBITDA | -60.64% | -26.85% | -40.28% | -25.48% | -26.30% |
| EPS Basic | 14.74% | 21.51% | 15.89% | 10.39% | -48.11% |
| Normalized Basic EPS | -19.86% | 21.52% | 15.89% | 10.39% | -5.38% |
| EPS Diluted | 14.74% | 21.51% | 16.48% | 10.39% | -47.09% |
| Normalized Diluted EPS | -19.86% | 21.52% | 15.89% | 10.39% | -5.38% |
| Average Basic Shares Outstanding | 27.53% | 40.27% | 39.71% | 24.69% | 10.39% |
| Average Diluted Shares Outstanding | 27.53% | 40.27% | 39.71% | 24.69% | 10.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |